Market News How it works Learn FAQ
| RCT 0.1222 60.58% | NU 12.375 -18.37% | EWZ 33.44 -21.48% | TGL 0.2449 10.56% | BBD 2.87 -29.48% | SRTM 0.3384 -21.36% | ITUB 7.555 -21.87% | AZTR 1.72 140.56% | XP 15.775 -48.13% | NVD 4.02 -4.06% | SHFS 0.0979 -26.06% | SPCX 148.81 0.89% | CLRO 4.75 46.15% | SOXL 90.94 8.83% | GCDT 0.1442 -18.11% | PBR 22 -15.90% | NWGL 0.0822 0.24% | VALE 11.895 -4.07% | TSLL 10.9402 12.09% | INTC 90.94 4.58% | SGRY 23.095 46.63% | CRWV 56.79 4.71% | NVDA 215.6 2.20% | BITO 10.6301 -1.85% | GPUS 0.1862 10.24% | SOXS 47.855 -8.78% | RBNE 0.17 -10.53% | NOK 8.6738 6.56% | ABEV 2.78 -15.76% | RWM 14.455 -0.65% | IREN 26.12 4.88% | JBLU 2.2648 -13.72% | INTR 4.525 -37.07% | TSLG 5.4701 12.32% | SBS 4.615 -27.89% | TQQQ 68.649 3.56% | XTND 2.1 18.64% | SPRC 1.5 37.61% | SPDN 8.4901 -0.58% | TSLA 395.035 6.13% | AAL 12.1593 0.41% | LUCD 0.5437 32.29% | SID 0.9326 -20.97% | SQQQ 38.275 -3.54% | PBR-A 19.3171 -17.90% | CIFR 7.9 -0.50% | GGB 4.725 -7.35% | T 21.035 0.50% | QID 14.195 -2.44% | NFLX 63.265 -3.93%
MNMannKind Corporation logo

MannKind Corporation (MNKD)

NASDAQ Global Market · Currency in USD
$3.19 ▼ -0.01 (-0.16%)
As of Oct 26, 1:22 PM ET. Market open.

Summary

Previous Close
$3.19
Open
$3.22
Day's Range
$3.17 – $3.28
52 Week Range
$2.23 – $6.51
Volume
972,043
Avg. Volume
4,620,978
Market Cap
$1.02B
Beta (5Y Monthly)
1.08
PE Ratio (TTM)
--
EPS (TTM)
-$0.14
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$10.00

Profile: MannKind Corporation

Sector
Healthcare
Industry
Biotechnology
Full-time employees
592
CEO
Michael E. Castagna

MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate -$0.06 · Revenue est. $107.74M
DateEst.Actual
Aug 5, 2026-$0.01-$0.06Miss
May 6, 2026-$0.02-$0.05Miss
Feb 26, 2026-$0.01-$0.05Miss
Nov 5, 2025$0.01$0.03Beat
Aug 6, 2025$0.04$0.00Miss
May 8, 2025$0.03$0.04Beat

Analyst view

Consensus price target
$10.00 ▲ +214.0%
Range $7.00 – $13.00
Rating: Buy
Buy 52% · Hold 14% · Sell 33%

Get free alerts on MNKD and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.